Money >

Wegovy Pill: New Data Reveals Sustained Weight Loss and Improved Physical Function

This article explores the latest clinical trial results for Novo Nordisk's oral obesity treatment, Wegovy, presented at the European Congress on Obesity. It delves into the sustained weight loss benefits, improvements in physical function, and a comparative analysis with another weight management drug, Orforglipron, offering a comprehensive overview of the drug's efficacy and patient preference.

Unlocking Sustained Weight Management: The Promise of Oral Semaglutide

Significant Weight Reduction Observed in Clinical Trials

Adults undergoing treatment with the 25 mg oral semaglutide formulation demonstrated notable weight loss, irrespective of their initial rate of reduction. This underscores the consistent efficacy of the medication across diverse patient responses.

Enhanced Long-Term Outcomes for Early Responders

A detailed evaluation revealed that individuals categorized as "early responders"—those who achieved at least a 10% body weight decrease by the sixteenth week—experienced an impressive average weight loss of 13.2% at that juncture. By the sixty-fourth week of the study, this group further solidified their progress, reaching an average reduction of 21.6% in body weight. Even participants who did not meet this early benchmark still reported a commendable average weight loss of 11.5% by the study's conclusion.

Wegovy's Impact on Physical Capabilities

Beyond weight loss, a separate analysis within the OASIS 4 study highlighted the positive influence of the oral Wegovy pill on physical well-being. Nearly 80% of participants struggling with impaired physical function reported clinically meaningful improvements in their functional scores, a stark contrast to the 42.9% observed in the placebo group. These scores assessed various physical attributes, including endurance and mobility. Novo Nordisk affirmed that patients in this subgroup achieved weight loss outcomes comparable to the broader treatment population.

Comparative Efficacy Against Orforglipron

Further analyses presented at ECO2026 suggested that the oral Wegovy pill not only delivered superior weight loss but also led to lower rates of treatment discontinuation due to gastrointestinal side effects when compared to orforglipron. This favorable profile was echoed in the OPTIC patient preference survey, where 84% of respondents expressed a preference for a treatment similar to the Wegovy pill over orforglipron.

Reinforcing the Core Findings of the OASIS 4 Trial

Novo Nordisk emphasized that these latest findings corroborate the primary results from the OASIS 4 trial. The original study showcased an average body weight reduction of 17% in adults treated with the oral Wegovy pill, significantly outperforming the 2.7% reduction seen in the placebo group. The company's shares reflected market activity, with a slight decrease of 0.11% at $46.95, while demonstrating a 26.4% gain over the past month, contrasting with the S&P 500's 9.1% rise.